Benitec Biopharma Inc. filed a Form 8-K on October 28, 2026, disclosing a press release announcing positive interim Phase 1b/2a clinical results for the high dose of BB-301 and continued durable improvements for the low dose of BB-301.

Key Highlights

  • Clinical update: The company announced positive interim Phase 1b/2a results for high dose BB-301, according to the filing.
  • Low dose findings: The filing also references continued durable improvements for low dose BB-301.
  • Disclosure mechanism: The update was issued via a press release furnished under Regulation FD (Item 7.01) and attached as Exhibit 99.1.
  • Exchange listing: Benitec Biopharma Inc. common stock (par value $0.0001) trades on NASDAQ:BNTC.
  • Signed by: Dr. Jerel A. Banks, Chief Executive Officer, on October 28, 2026.

Benitec Biopharma Discloses BB-301 Interim Clinical Data via October 2026 Regulation FD Filing

On October 28, 2026, Benitec Biopharma Inc. (NASDAQ:BNTC), a Delaware-incorporated biopharmaceutical company headquartered in Hayward, California, filed a current report under Item 7.01 (Regulation FD Disclosure) to announce interim clinical results for its BB-301 program. According to the filing, the press release furnished as Exhibit 99.1 covers "positive interim Phase 1b/2a results for high dose BB-301 and continued durable improvements for low dose BB-301."

The filing specifies that the information contained in Item 7.01, including Exhibit 99.1, "shall not be deemed to be 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section." The company also disclosed that the information shall not be incorporated by reference into any other filing unless expressly incorporated by specific reference.

The report was signed by Dr. Jerel A. Banks, Chief Executive Officer of Benitec Biopharma Inc., on October 28, 2026. The company's common stock carries a par value of $0.0001 per share and is registered on The Nasdaq Stock Market LLC under the trading symbol BNTC. The filing notes the company is not classified as an emerging growth company.

What Was Disclosed

Benitec Biopharma filed an 8-K on October 28, 2026, furnishing a press release under Regulation FD that reported positive interim Phase 1b/2a results for high dose BB-301 and continued durable improvements for low dose BB-301. The press release is attached as Exhibit 99.1.